Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922785 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TP53TDP1RAB9ACFTR | |
| SCHEMBL922016 | 0.89 | TDO2 (0.40) | TP53RAB9ACFTRGOPCLMNA | |
| SCHEMBL923300 | 0.83 | DEPTOR (0.46) | ALDH1A1TDP1RAB9ALMNANPC1 | |
| SCHEMBL923301 | 0.83 | DEPTOR (0.46) | ALDH1A1TDP1RAB9ALMNANPC1 | |
| SCHEMBL922520 | 0.82 | KMT2A (0.36) | ALDH1A1TP53RAB9ALMNATDO2 | |
| SCHEMBL922521 | 0.82 | KMT2A (0.36) | ALDH1A1TP53RAB9ALMNATDO2 | |
| SCHEMBL923909 | 0.79 | MAPT (0.37) | ALDH1A1TP53RAB9ACFTRGOPC | |
| SCHEMBL923911 | 0.79 | MAPT (0.37) | ALDH1A1TP53RAB9ACFTRGOPC | |
| SCHEMBL922330 | 0.78 | DDB1 (0.35) | ALDH1A1TP53LMNATDO2KMT2A | |
| SCHEMBL922331 | 0.78 | DDB1 (0.35) | ALDH1A1TP53LMNATDO2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | claimed |
| CN-1671379-A | Hydrazinopyrazole derivatives and their use as therapeutic agents | QUADRA LOGIC TECH INC (CA) | 2005-09-21 | — | — | CN | claimed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | claimed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1671379-A | Hydrazinopyrazole derivatives and their use as therapeutic agents | QUADRA LOGIC TECH INC (CA) | 2005-09-21 | — | — | CN | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | ALDH1A1 1614/4885TP53 8/4885TDP1 646/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | ALDH1A1 1614/4885TP53 8/4885TDP1 646/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | ALDH1A1 3393/4885TP53 5/4885TDP1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.